Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20⁺ non-Hodgkin’s lymphoma

Bibliography

• Eisenbeis CF, Caligiuri MA, Byrd JC, et al. Rituximab: converging mechanisms of action in non-Hodgkin’s lymphoma? Clin Cancer Res 2003;9:5810-12
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal antiCD20 antibody): mechanisms of action and resistance. Oncogene 2004;22:7359-68
   Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-5
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7(5):379-91
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31
   PubMed Web of Science ®Google Scholar
• Mabthera. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Summary_for_the_public/human/000165/WC500025815.pdf [2010]
   Google Scholar
• Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007;109:4171-3
   PubMed Web of Science ®Google Scholar
• Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-71
   PubMed Web of Science ®Google Scholar
• Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. Blood 1999;17:791-5
   Google Scholar
• Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64
   PubMed Web of Science ®Google Scholar
• Aurran-Schleinitz T, Gravis G, Vittot M, et al. One hour rituximab infusion is safe and improves patient care and outpatient unit management. Blood 2005;106:abstract 4759
   Google Scholar
• Middleton H, Mollee P, Bird R, et al. Accelerated delivery of rituximab is safe on an out-patient basis. Blood 2005;106:abstract 4777
   Google Scholar
• Salar A, Casao D, Cervera M, et al. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 2006;77:338-40
   PubMed Web of Science ®Google Scholar
• Tuthill M, Crook T, Corbet T, et al. Rapid infusion of rituximab over 60 min. Eur J Haematol 2009;82:322-5
   PubMed Web of Science ®Google Scholar
• Provencio M, Cerdeira S, Bonilla F, et al. Rapid infusion rituximab in lymphoma treatment. Ann Oncol 2006;17(6):1027-8
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Rituximab infusion. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm324890.htm [Page Last Updated 22 October 2012]
   Google Scholar
• US National Institutes of Health, ClinicalTrials.gov. A study of rituximab alternative dosing rate in patients with previously untreated diffuse large B-cell or follicular non-Hodgkin’s lymphoma (RATE). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00719472?term=RATE&rank=4
   Google Scholar
• Yokoyama M, Terui Y, Takeuchi K, et al. Infusion Rate Escalation Study of rituximab in patients with CD20+ B-cell lymphomas: a single institution analysis in Japan. ISRN Oncol 2013;3:863909
   Google Scholar
• Witzens-Harig M, Foá R, Di Rocco A, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 2014;93(10):1717-24
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381(9880):1817-26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013-22
   PubMed Web of Science ®Google Scholar